Acerta Pharma

Developing the leading second-generation BTK inhibitor

Acerta is developing the leading second-generation BTK inhibitor for the treatment of hematologic malignancies and severe diseases of inflammation. The company has operations in Oss, the Netherlands and multiple U.S. sites. Its U.S. headquarters is in Redwood City, CA. Acerta was acquired by AstraZeneca in 2016.

Status

Acquired by AstraZeneca in 2016

Year of Investment

2013

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

The Netherlands